Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

clinical trial

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02184416

P17countrySpainQ29
BelgiumQ31
ItalyQ38
AustriaQ40
FranceQ142
United KingdomQ145
P582end time2019-07-20
P1050medical conditioncarcinomaQ33525
P2899minimum age18
P1132number of participants750
P4844research interventionsirolimusQ32089
P6153research siteSalamanca University HospitalQ87762406
Barcelona ProvinceQ81949
Complutense University of MadridQ219694
Jean Perrin CenterQ2944826
Hôpital Lyon SudQ2945675
hôpital FochQ3145155
Clínica Universidad de NavarraQ3297837
IRCCS Policlinico S. Matteo di PaviaQ3747180
Residencia Sanitaria General YagüeQ5902662
Hospital de LeónQ5903037
Hospital Universitario de CanariasQ5908655
Royal Surrey County HospitalQ7374889
Hospital General Universitario de AlicantetQ16576057
Hospital Virgen de la SaludQ30254321
Centre Hospitalier De PauQ50036402
???Q2945710
P1813short nameADONIS
P580start time2014-10-31
P8363study typeobservational studyQ818574
P1476titleAxitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)